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Abstract
Background: Master transcription factor MyoD can initiate the entire myogenic gene expression program which
differentiates proliferating myoblasts into multinucleated myotubes. We previously demonstrated that histone
methyltransferase KMT1A associates with and inhibits MyoD in proliferating myoblasts, and must be removed to allow
differentiation to proceed. It is known that pro-myogenic signaling pathways such as PI3K/AKT and p38α MAPK play
critical roles in enforcing associations between MyoD and transcriptional activators, while removing repressors.
However, the mechanism which displaces KMT1A from MyoD, and the signals responsible, remain unknown.
Methods: To investigate the role of p38α on MyoD-mediated differentiation, we utilized C2C12 myoblast cells as
an in vitro model. p38α activity was either augmented via overexpression of a constitutively active upstream kinase or
blocked via lentiviral delivery of a specific p38α shRNA or treatment with p38α/β inhibitor SB203580. Overexpression of
KMT1A in these cells via lentiviral delivery was also used as a system wherein terminal differentiation is impeded by
high levels of KMT1A.
Results: The association of KMT1A and MyoD persisted, and differentiation was blocked in C2C12 myoblasts specifically
after pharmacologic or genetic blockade of p38α. Conversely, forced activation of p38α was sufficient to activate MyoD
and overcome the differentiation blockade in KMT1A-overexpressing C2C12 cells. Consistent with this finding, KMT1A
phosphorylation during C2C12 differentiation correlated strongly with the activation of p38α. This phosphorylation was
prevented by the inhibition of p38α. Biochemical studies further revealed that KMT1A can be a direct substrate
for p38α. Importantly, chromatin immunoprecipitation (ChIP) studies show that the removal of KMT1A-mediated
transcription repressive histone tri-methylation (H3K9me3) from the promoter of the Myogenin gene, a critical
regulator of muscle differentiation, is dependent on p38α activity in C2C12 cells. Elevated p38α activity was also
sufficient to remove this repressive H3K9me3 mark. Moreover, ChIP studies from C2C12 cells show that p38α
activity is necessary and sufficient to establish active H3K9 acetylation on the Myogenin promoter.
Conclusions: Activation of p38α displaces KMT1A from MyoD to initiate myogenic gene expression upon induction of
myoblasts differentiation.
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Background
Differentiation of myogenic precursor myoblast cells
into a multinucleated contractile myofiber is a tightly
regulated multistep process essential during development,
in adulthood, and is often perturbed in pathological condi-
tions. This process demands a precise, highly coordinated,
temporally ordered myogenic gene expression program
[1] and proceeds through a feed-forward mechanism [2].
The discovery of MyoD [3], the founding member of the
myogenic regulatory factors (MRFs) that include Myf5,
MRF4, and myogenin, demonstrated its action as a key
master regulator of myoblast determination and subse-
quent differentiation into myotube [4–8]. Initiation of the
myogenic differentiation by MyoD requires cooperation
with a number of ubiquitous transcriptional regulatory
factors. These include chromatin modifiers that synergis-
tically activate muscle-specific gene expression in myo-
blasts undergoing differentiation [4–6, 9–14]. Similarly,
MyoD also directly interacts with components of the basal
transcriptional machinery [15–17]. Understanding these
interactions of MyoD provide insight into mechanisms
guiding the activation of myogenic gene expression pro-
gram in myoblasts upon induction of differentiation.
Although MyoD is able to execute the entire differen-
tiation program, it is expressed in undifferentiated myo-
blasts [5, 7, 18]. Paradoxically, MyoD binding analysis
revealed its broad occupancy throughout the genome in
myoblasts, indicating that its DNA binding alone is not
sufficient to activate myogenic gene expression and drive
differentiation [5, 19]. Dissection of myogenic differen-
tiation revealed complex epigenetic control of the gene
expression program. Accordingly, switching myoblasts
from proliferation into differentiation is underpinned
by specific epigenetic events to transition myogenic
loci from a transcriptionally repressive to activating
state. This is caused by chromatin-associated activities,
ranging from covalent modification of histones and
myogenic regulatory factors to chromatin remodeling
[4, 10, 14, 20, 21]. In growing myoblasts, MyoD-bound
muscle-specific genes are generally epigenetically marked
for transcriptional repression through trimethylation of
histone H3 at Lys9 (H3K9me3) and/or Lys27 (H3K27me3)
on promoter/enhancer regions to control their temporal
expression [21–25]. Specifically, we demonstrated that
H3K9me3-specifc enzyme KMT1A is recruited to the
myogenin (Myog) promoter by associating with MyoD,
which establishes a H3K9me3-mediated repressive chro-
matin environment to prevent premature differentiation
[26]. Subsequent data revealed that displacement of
KMT1A from MyoD at the onset of differentiation cou-
ples with eradication of the repressive H3K9me3 mark
and activation of MyoG, a critical regulator in patterning
myogenic differentiation-specific gene expression through
a feed-forward network with MyoD [1, 2, 27].
An essential step in establishing active transcription at
myogenic loci is the temporal recruitment of specific
chromatin modifiers that promote MyoD-orchestrated
myogenic gene expression and differentiation [10, 14, 20].
At the onset of myoblast differentiation, predominant
signaling pathways such as p38α MAPK and PI3/AKT
play a major role in transitioning from a transcription-
ally repressive to permissive chromatin environment for
MyoD-initiated myogenic differentiation program [28–32].
By contrast, p38γ MAPK represses myogenic differenti-
ation by facilitating the association of MyoD with KMT1A
in growing myoblasts [33]. Recent studies have also indi-
cated that it is critical to remove repressive H3K9me3 and
H3K27me3 marks from myogenic promoter/enhancer re-
gions upon reception of the differentiation-promoting sig-
nals. This is carried out by histone demethylases, including
JMJD2A [34] and UTX [35]. However, the signaling path-
way(s) that control the removal of KMT1A from MyoD,
thereby antagonizing KMT1A-dependent H3K9me3 and
facilitating the switch from repression into activation of
myogenic genes at the onset of differentiation, remains
enigmatic.
Here, we identify that p38α MAPK disables MyoD-
KMT1A association by phosphorylating KMT1A, thereby
permitting a switch from transcriptionally repressive
H3K9me3 to active H3K9 acetylation (H3K9ac) [36] in
the promoter of important muscle differentiating regu-
lator MyoG. Interference of p38α activity or expression
inhibited phosphorylation of KMT1A and prevented its
release from MyoD, resulting in sustained H3K9me3-
mediated repression of Myog and impaired myogenic
differentiation. Conversely, forced activation of p38α
releases KMT1A from MyoD, resulting in MyoG ex-
pression and differentiation. Therefore, this study un-
veils a new role for p38α as an essential signaling
effector of KMT1A phosphorylation to unleash its asso-




Human 293A and 293FT and mouse C2C12 myoblasts
have been used previously [26, 37, 38]. C2-4RE-luc reporter
cells expressing MyoD-responsive 4RE-luc luciferase gene
in C2C12 have been described previously [37]. Human
primary skeletal myoblast cells (HsMB) were purchased
from Lonza. Except C2C12, C2-4RE-luc, and HsMB, all
cells were cultured in DMEM medium containing 10 %
FBS supplemented with antibiotic-antimycotic (Invitrogen).
C2C12 myoblasts were cultured in growth medium (GM,
20% FBS) and induced to differentiate by switching in dif-
ferentiation media (DM) medium as described previously
[26]. HsMB cells were cultured in growth medium
(SKGM-2BulletKit, Lonza) and induced to differentiate
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by switching to DM. For p38α/β MAPK or PI3K/AKT
inhibition studies, SB203580 (SB) and LY294002 (LY)
(Calbiochem) were added directly to DM at a final concen-
tration of 5 and 20 μM, respectively. For Flag-KMT1A,
HA-MKK6EE, or HA-MKK6DN overexpression studies,
cells were transduced with lentivirus expressing with indi-
cated gene or without (empty). Likewise, for knockdown of
KMT1A or p38α, lentivirus expressing respective shRNA
or random scramble shRNA was transduced into the cells.
All cells were grown at 37 °C, 5 % CO2 in a humidified
atmosphere.
Lentiviral production and transduction
Lentiviruses were produced in 293FT cells as previously
described [26]. Briefly, cells were transfected with lentiviral
vector along with packaging vectors using Pure-Fection
transfection reagent (System Biosciences). Virus-containing
supernatants were collected and filtered. Viruses were
diluted with growth medium and transduced three con-
secutive days in the presence of 8 μg/ml of polybrene
(Sigma-Aldrich). Where applicable, virus-transduced cells
were subjected to selection against puromycin (1–2 μg/ml)
for 2–3 days.
Vectors and antibodies
Lentiviral pLV vector expressing Flag-KMT1A [38] and
LV-HA-MKK6EE and pLV-HA-MKK6DN were gener-
ated by subcloning inserts from pcDNA-HA-MKK6EE
and pcDNA-HA-MKK6DN (provided by Dr. L. Puri) [39]
into pLV vector. For expression of shRNA, KMT1A, p38α,
or scramble shRNAs are cloned individually into lentiviral
pLKO.1-TRC vector (Addgene) and sequence verified.
The shRNA sequences for KMT1A and scramble were
described previously [38]. The sequence for p38α
shRNA was 5′-AGCCCAGCAACCTAGCTGTTT-3′.
Vectors pGEX-4T-3-H3(N) [26] and pGEX-ATF2
(provided by Dr. J. Han) [40] express GST fusion N-
terminal histone H3 and ATF2 proteins, respectively.
Antibodies used were phospho-p38 (Cell Signaling
9215), β-actin-peroxidase (Sigma A3854), Flag-M2
(Sigma F3165), myogenin (BD Pharmingen 556358),
KMT1A (Cell Signaling 8729, and Millipore 07-550
and 05-615), MyoD (Santa Cruz sc-760 and BD Pharmin-
gen 554130), p38α (Cell Signaling 9790), HA-peroxidase
(Sigma H6533), acetyl-histone H3 (Millipore, 06-599),
trimethyl-histone H3 (Lys-9) (Millipore 07-442), trimethyl-
histone H3 (Lys27) (Millipore 07-449), GAPDH (Biodesign
H86504M), Brg-1 (Santa Cruz sc-10768), p21cip1 (Santa
Cruz sc-397), myosin heavy chain (Developmental
Studies Hybridoma Bank, MF-20), total p38 (Cell
Signaling 9212), and normal rabbit IgG (Santa Cruz
sc-2027).
Cell extracts, immunoprecipitation, and western blot
analysis
Preparation of cell extracts, immunoprecipitation, and
western blot analysis were described previously [18]. For
both immunoprecipitation coupled or direct western
blot analysis, the signal was detected using ECL reagents
(GE Healthcare) and the image was retrieved and
analyzed by Alpha Innotech FluorChem® HD2 Imager
(R&D systems).
Purification of protein and reporter luciferase assay
Purification GST and GST fusion H3(N) and ATF2 fusion
proteins from bacteria were carried out as previously des-
cribed [18]. Reporter luciferase assay was performed as
described [37]. Luciferase activity was determined using
the luciferase assay system (Promega) and normalized
with protein concentration determined by DC protein
assay reagent (Bio-Rad).
Histone methyl transferase (HMT) activity and
kinase assays
The HMT activity assay was performed as described pre-
viously [26]. Briefly, control normal IgG or anti-MyoD
immunoprecipitates retrieved from equivalent amount
of cells extracts were subjected to HMT assay buffer
supplemented with 2.5 μg bacterially purified GST-
H3(N) and 1.0 μCi of [3H]SAM and incubated for 1 h
at 30 °C. Reaction mixtures were resolved by SDS-
polyacrylamide gel electrophoresis followed by fluorog-
raphy and autoradiography.
The kinase assay was performed as described previously
[41]. In brief, control normal IgG or anti-phospho-p38 im-
munoprecipitates captured from equivalent amount of cell
extracts were incubated with kinase assay buffer in the
presence of 10 μCi [γ-32P]-ATP with bacterially purified
GST-ATF2 substrate for 1 h at 30 °C. To monitor KMT1A
phosphorylation directly by p38α, kinase assay was per-
formed by incubating anti-Flag-M2 immunoprecipitates,
which was retrieved from 293A cell extracts expressing
with or without ectopic Flag-KMT1A, supplemented with
purified active p38α (Millipore 14-587) and [γ-32P]-ATP
in the presence or absence of SB. For control, kinase assay
was performed as above using GST-ATF2 as substrate
supplemented with purified active p38α.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed in C2C12 cells grown in
GM or in DM for 2 days in the presence and absence of
SB according to the method as described previously [26].
ChIP also performed after overexpression of MKK6EE or
empty in C2C12 cells treated with SB in GM. Briefly,
equivalent amount of chromatin samples (normalized
by A260) prepared from HCHO-crosslinked cells were
subjected to immunoprecipitates with specific antibody
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or control normal IgG followed by DNA purification and
semi-quantitative PCR analysis or the E-box sites located at
the promoter regions of Myog and MyHCIIB using specific
primers. As an input control for ChIP, PCR was performed
with DNA from chromatin prior to immunoprecipitation
(0.03 % total chromatin used for ChIP) using primers that
also amplify the same promoter regions of the above genes.
Primers used for Myog were described previously [26]. For




products were fractionated by polyacrylamide gel
electrophoresis and visualized by autoradiography.
Immunofluorescence
Immunofluorescence was performed as previously de-
scribed [18]. In brief, cells grown in 35-mm culture
dishes were fixed with chilled methanol (20 %), rehydrated,
blocked with 3 % BSA, washed with PBS containing 0.1 %
NP-40, and then incubated with anti-MyHC (MF20)
antibody. Alexa-Fluor 488 conjugated secondary anti-
body (Invitrogen) was used to detect the bound primary
MF20 antibody. Images were acquired with a ×10 ob-
jective lens using fluorescence microscope Leica DMI
4000 B (Leica microsystems).
Results
Activation of p38α abolishes MyoD-associated H3
methyltransferase activity during differentiation
We demonstrated that KMT1A directly interacts with
MyoD, leading to MyoD-associated histone methyl-
transferase (HMTase) activity which impedes myoblast
differentiation, and that release of KMT1A from MyoD
abolishes this HMTase activity to promote differentiation
[26]. Since differentiation-activated p38α and PI3/AKT
signaling cascades promote MyoD-mediated myogenic
gene expression [29, 31, 43–45], we asked whether either
of these signaling pathways are involved in this removal
of KMT1A from MyoD during myoblast differentiation.
Hence, we examined MyoD-associated HMTase activity
to monitor KMT1A interaction with MyoD in C2C12
myoblasts cultured in GM or DM with either vehicle,
p38α/β inhibitor SB20325 (SB), or PI3/AKT inhibitor
LY294002 (LY). Results show a loss of MyoD-associated
KMT1A activity in differentiated (DM) but not in growing
myoblasts (GM) as demonstrated previously by us (Fig. 1a)
[26]. Intriguingly, this MyoD-associated activity persists in
SB but not in LY-treated C2C12 cells grown in DM. The
observed disparity of MyoD-associated KMT1A activity
was not due to an unequal amount of substrate revealed
by coomassie of histone H3(N) [26] or a variation of
MyoD protein levels, which are not altered in C2C12 cells
exposed either with SB or LY [31], and verified in immu-
noprecipitates by western blot analysis (data not shown).
Inhibition of p38α/β by SB or PI3K/AKT by LY represses
MyoD myogenic activity on target genes at chromatin
levels during myoblasts differentiation [31, 46]. Consist-
ently, results show the repression of chromatin-integrated
MyoD-responsive 4RE reporter luciferase gene activation
in C2C12-derived C2-4RE-luc reporter cells [47] grown in
DM treated either with SB or LY (Fig. 1b), assuring the in-
hibition of the respective pathways by SB or LY in our
experimental setting. Together, these findings strongly
suggest that activation of p38α/β, but not the PI3/AKT
pathway, enables the removal of MyoD-associated KMT1A
activity in C2C12 myoblasts induced to differentiate. Al-
though SB treatment inhibits p38α/β isoforms to prevent
myogenic gene expression and differentiation of C2C12
cells [44, 48, 49], functional analysis has demonstrated that
these effects are mediated exclusively by p38α in these
cells and in mice [29, 50]. We evaluated p38α-specific
Fig. 1 Pharmacological blockade of p38α signaling precludes unleashing of MyoD-associated HMT activity during myoblasts differentiation. a MyoD or
control IgG immunoprecipitates retrieved from cell extracts of C2C12 grown in GM or DM with or without SB or LY were subjected to HMT activity
assay. Methylated and input H3(N) were detected by fluorography and Commassie, respectively. b Luciferase activity was assessed in C2-4RE-luc
reporter cells grown in GM or DM without or with SB or LY. Luciferase activity was expressed after protein normalization as fold activation. Error bar,
±SEM (n = 3). c Western blot analysis of primary HsMB cells expressing shRNA of scramble control shRNA (Ctrl) or p38α via lentiviral delivery grown in
GM or DM with or without SB, probed with antibodies for indicated proteins. β-actin served as loading control
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contributions in HsMb differentiation following its
downregulation via lentiviral delivery of p38α shRNA
compared to control shRNA (Ctrl) (Additional file 1:
Figure S1). For this purpose, we examined the protein
expression levels of differentiation-associated muscle-
specific genes, such as early MyoG and late myosin
heavy chain (MyHC), in HsMb cells expressing p38α
shRNA induced to differentiate in DM. Cells expressing
Ctrl shRNA were cultured in GM or DM with vehicle or
SB. Results show inhibited expression of these muscle-
related genes in both SB-treated and p38α-depleted cells
compared to control cells in DM (Fig. 1c). Results also
confirmed the inhibition of p38 activation in SB-treated
cells cultured in DM, as phospho-p38 but not total p38α
was suppressed in these cells, similar to control cells cul-
tured in growth conditions (GM). As expected, p38α de-
pletion is correlated with decreased phospho-p38 levels in
these cells grown in DM. Moreover, MyoD protein levels
were detected in all cells cultured in DM. Thus, the
anti-myogenic effect of SB, and the persistent MyoD-
associated KMT1A activity in SB-treated cells (Fig. 1a),
is mainly due to blockade of p38α activation, suggesting
that its activation displaces KMT1A activity from MyoD
during muscle differentiation.
Forced p38α activation suppresses KMT1A
overexpression-inhibited MyoD activity
Studies have shown that activation of the p38 pathway,
by forced expression of a constitutively active allele of its
upstream kinase MKK6 (MKK6EE) [40, 51], activates
MyoD-regulated gene transcription in myoblasts cultured
in conditions non-permissive for differentiation such as
GM media [2, 31, 44]. Since KMT1A overexpression can
repress this activity of MyoD during C2C12 differentiation
[26], we asked if MKK6EE overexpression can overcome
the repressive effect of KMT1A on MyoD. Accordingly,
Flag-tagged KMT1A overexpressing C2-4RE-luc reporter
cells (C2-4RE-luc/KMT1A-F) were generated via lentiviral
delivery. Western blot analysis verifies the expression of
Flag-KMT1A along with an increase of total KMT1A and
endogenous MyoD levels in these cells compared to
parent C2-4RE-luc cells (Additional file 2: Figure S2A).
KMT1A overexpression-induced inhibition of MyoD
activity was verified by its responsive 4RE reporter gene
activation and differentiation-induced MyoD expression
in C2-4RE-luc/KMT1A-F cells relative to C2-4RE-luc
cells in DM (Fig. 2a). We then overexpressed HA-
tagged MKK6EE (herein referred as MKK6EE) in this
cell background via lentiviral delivery and measured its
effect on MyoD-responsive reporter gene activation
compared to cells transduced with empty (Em) vector
control lentivirus. Data shows that MKK6EE was sufficient
to induce MyoD activity in C2-4RE-Luc/KMT1A-F cells
in GM (Fig. 2b), similarly to its effect in parent C2-4RE-
Luc reporter cells (Additional file 2: Figure S2B). More-
over, the data shows that overexpression of a dominant
negative form of MKK6 (MKK6DN, also tagged with HA)
via the same manner fails to induce MyoD-responsive
reporter gene activation in these cells grown in GM
(Fig. 2b and Additional file 2: Figure S2B), indicating
that this induction is dependent on the kinase activity
of MKK6 and not the protein directly. Importantly, the
Fig. 2 MKK6EE-p38α activation can abolish KMT1A inhibited gene activation by MyoD. a C2-4RE-luc/KMT1A-F cells were generated by overexpression of
Flag-KMT1A in C2-4Re-luc reporter cells by lentiviral delivery. Subsequently, luciferase activity was assessed in C2-4RE-luc and C2-4RE-luc/KMT1A-F cells in
GM or DM and expressed protein after normalization as fold activation. Western blot analysis of these reporter cells extracts probed with antibodies to
detect MyoD and β-actin for loading control. b Luciferase activity was assessed in C2-4RE-luc/KMT1A-F cells following expression of MKK6EE, MKK6DN or
vector control (Em) via lentiviral delivery grown in GM and expressed after protein normalization as fold activation. c C2-4RE-luc/KMT1A-F cells expressing
vector control (Em) or MKK6EE via lentiviral delivery were grown in GM or DM and MKK6EE-transduced cells treated with or without SB.
Afterward, luciferase activity was assessed in these cells and values expressed after protein normalization. Where appropriate, error bar, ±SEM (n = 3)
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effect of MKK6EE on MyoD-mediated reporter gene
activation was inhibited following SB treatment in C2-
4RE-Luc/KMT1A-F cells grown either in GM or DM
(Fig. 2c), suggesting that this induction of MyoD activity is
indeed dependent on p38α activation in these cells. Taken
together, these data demonstrate that upstream activa-
tion of MKK6-p38α signaling can overcome KMT1A-
mediated repression of MyoD activity during myoblast
differentiation.
Elevated p38α activity can overcome KMT1A
overexpression impeded differentiation
Since elevated p38α activity is sufficient to restore
KMT1A-inhibited MyoD activity in C2-4RE-Luc/KMT1A-
F cells (Fig. 2b, c), we asked if this finding would be
corroborated by phenotypic differentiation, which is im-
paired by KMT1A overexpression in C2C12 cells as
previously demonstrated by us [26]. Consistently, results
show that Flag-KMT1A overexpression in C2C12 cells
(C2-KMT1A-F) via lentiviral delivery inhibited the dif-
ferentiation related expression of MyHC, MyoG, MyoD,
and p21cip1 proteins levels relative to vector control
virus-transduced cells (C2-Em) grown in DM (Fig. 3a).
However, elevation of p38 activation via MKK6EE overex-
pression resulted in induced levels of the above proteins in
C2-KMT1A-F cells grown in GM and with a greater
efficiency in DM. Western blot analysis confirmed
MKK6EE-induced activation of p38 as revealed by in-
creased phospho-p38 levels in these cells (Additional
file 3: Figure S3). Results also show that this induction
of differentiation-related proteins by MKK6EE oc-
curred in a p38α activation-dependent manner. Further-
more, MKK6EE-induced activated phospho-p38 and
differentiation-related proteins levels were suppressed in
Fig. 3 MKK6EE-p38α activation can rescue KMT1A suppressed muscle differentiation. a Western blot analysis of cell extracts from vector control
C2-Em and Flag-KMT1A overexpressing C2-KMT1A-F cells generated via lentiviral delivery and the same cells after MKK6EE expression by same
delivery system grown in GM or DM with or without SB. Probed with antibodies for indicated proteins where β-actin served as loading control.
b Same as a except for western blot analysis, cells were fixed and evaluated for morphology by phase contrast microscopy and immunostained with
anti-MyHC antibody (MF20)
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C2-KMT1A-F cells either in GM or DM following SB
treatment (Fig. 3 and Additional file 3: Figure S3). To-
gether, these findings suggest that MKK6EE-p38α activa-
tion overcomes the impairment of differentiation-related
gene activation in C2-KMT1A-F cells on induction of dif-
ferentiation. We then asked whether these results were
reflected in phenotypic morphological differentiation by
monitoring the ability of C2-Em and C2-KMT1A-F cells
to form multinucleated myotubes and express terminal
differentiation marker MyHC via immunofluorescence.
The data confirms multinucleated myotube formation and
MyHC expression are prevented in C2-KMT1A-F cells
compared to C2-Em cells grown in DM (Fig. 3b). Con-
versely, results show that MKK6EE overexpression was
sufficient to revert this phenotypic differentiation block in
C2-KMT1A-F cells both in GM and DM, while treatment
with SB abolished this effect of MKK6EE. These results in-
dicate that the effect of elevated p38α activity on KMT1A
overexpression-imposed block of MyoD activity in C1C12
cells is reflected in the phenotypic differentiation of these
cells. Taken together, these data suggest that activation of
p38α overcomes KMT1A-mediated repression of MyoD
to permit terminal differentiation of myoblasts.
p38α activation-dependent phosphorylation of KMT1A
associates with differentiation
Our previous study demonstrated that KMT1A is phos-
phorylated during muscle differentiation and hypothe-
sized that differentiation-induced kinase(s) may result in
phosphorylation of KMT1A [26]. Since results above
clearly indicate that elevated p38α activity overcomes
suppression of MyoD activity by KMT1A overexpression
to induce differentiation of C2C12 cells (Figs. 2 and 3),
we inquired about the status of phosphorylated KMT1A
in these cells after altering p38 activity by overexpression
of MKK6EE or MKK6DN compared to vector control
(Em) via lentiviral delivery. Western blot analysis con-
firmed that MKK6EE, but not MKK6DN, induced activa-
tion of both p38 and muscle differentiation as revealed by
induced levels of phospho-p38 and differentiated related
p21cip1, MyoG, and MyHC compared to control cells cul-
tured in GM (Fig. 4a). C2C12 cells cultured in DM were
used as a positive control. Importantly, only MKK6EE
overexpression resulted in increased levels of phosphory-
lated KMT1A, which was also detectable in C2C12 cells
cultured in DM, indicating that phosphorylation of
KMT1A occurs upon activation of p38 in these cells.
This pattern of phosphorylated KMT1A was also ob-
served following re-probing with a separate KMT1A
antibody (Additional file 4: Figure S4A). Moreover, this
intense band from differentiated C2C12 cells was dimin-
ished after depletion of KMT1A via lentiviral shRNA-
mediated knockdown (Additional file 4: Figure S4B),
confirming that this band is indeed KMT1A. We next
sought to determine the kinetics of KMT1A phosphoryl-
ation and p38 activation in C2C12 cells induced to differ-
entiate. Western blot analysis shows the appearance of
phosphorylated KMT1A at 1.5 days which was more pro-
nounced at 2 days in DM (Fig. 4b). Moreover, phosphoryl-
ation of KMT1A strongly correlated with increased levels
of activated phospho-p38 and higher expression of p21cip1
and MyoG. To test whether this KMT1A phosphorylation
is indeed dependent on differentiation-induced p38α ac-
tivity, C2C12 cells were induced to differentiate in DM
after treating cells with or without SB. Western blot ana-
lysis shows that SB treatment-induced inhibition of p38
(phospho-p38) blocks the phosphorylation of KMT1A in
addition to inhibiting p21cip1 and MyoG (Fig. 4c), sug-
gesting that apparently p38α activation directs KMT1A
phosphorylation during C2C12 differentiation. To con-
firm that this effect of SB on KMT1A phosphorylation
is through p38α, phosphorylated levels of KMT1A was
evaluated by western blot analysis of C2C12 cells ex-
pressing control shRNA (Ctrl) grown in GM or induced
to differentiate while expressing Ctrl or p38α shRNA in
DM. Results show that p38α depletion, resulting in a
lack of activated phospho-p38, indeed blocks KMT1A
phosphorylation in these cells (Fig. 4d). Moreover, in-
hibition of MyHC expression in p38α-depleted cells in
DM is consistent with previous studies specifically im-
plicating p38α in myogenic differentiation [29, 50]. We
also asked whether p38α may be directly responsible
for this phosphorylation of KMT1A. Therefore, Flag-
KMT1A was overexpressed in 293A cells (Additional
file 4: Figure S4C) and immunoprecipitated with anti-
Flag (M2) antibodies or control IgG from extracts of
cells expressing Em or Flag-KMT1A. Subsequently, an
in vitro kinase assay coupled with western blot analysis
was performed after the addition of purified active
p38α to these immunoprecipitates with or without SB.
Results show phosphorylation of immunoprecipitated
Flag-KMT1A protein directly by p38α, which is blocked
in the presence of SB (Fig. 4e). The activities of both p38α
and SB were verified by performing a similar kinase assay
using bacterially purified known p38 kinase substrate
ATF2 (Additional file 4: Figure S4D). Together, these re-
sults indicate that phosphorylation of KMT1A associates
with differentiation of myoblasts and that this phosphoryl-
ation is specifically dependent on the activation of p38α.
Phosphorylation of KMT1A by p38α relieves MyoD during
differentiation
Based on the above results, we hypothesized that p38α-
mediated phosphorylation of KMT1A results in its release
from MyoD, thereby rescuing KMT1A impeded MyoD
activity in myoblasts proceeding to differentiation. To test
this, we examined MyoD-associated KMT1A and corres-
ponding HMTase activity by analyzing of anti-MyoD
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immunoprecipitates from C2C12 cells grown in GM or
DM without or with SB to block p38α activation. Con-
sistent to our previous study [26], results of western as
well as HMTase activity assays show that KMT1A and
its HMTase activity are associated with MyoD in cells
before (GM) but not after induced to differentiate in
DM without SB (Fig. 5a). In contrast, persistent levels
of both MyoD-associated KMT1A and HMTase activity
were observed in cells that have been in DM with SB.
Western analysis also shows no disparity in the levels of
MyoD recovered from extracts these cells. Accordingly,
western analysis of anti-KMT1A immunoprecipitates
shows MyoD association with KMT1A in cells grown
in GM or DM with, but not without, SB. Western also
confirms that an equivalent level of KMT1A recovered
from these cells (Fig. 5b). Together, these findings show
that activated p38α activity is necessary to remove
KMT1A from MyoD at the induction of C2C12 cell
differentiation.
We then asked whether elevated p38α activity was suf-
ficient to remove KMT1A from MyoD at the onset of
myoblast differentiation. To address this, we examined
Fig. 4 p38α mediates phosphorylation of KMT1A during myoblasts differentiation. a Western blot analysis of cell extracts from C2-4RE-luc/KMT1A-F
expressing control vector (Em), MKK6EE or MKK6DN via lentiviral delivery grown in GM, and C2C12 grown in DM as positive control of differentiation,
probed with antibodies for indicated proteins, and β-actin as for loading control. Phosphorylated KMT1A was detected C2-4RE-luc cells expressing only
MKK6EE in GM and C2C12 cells in DM. b Western blot analysis of cell extracts from C2C12 grown in GM or DM at various time points, probed with
antibodies for detecting indicated proteins, GAPDH as loading control. An increased level of phosphorylated KMT1A was observed with increased
activated p38 status during the differentiation of C2C12 myoblasts. c Western blot analysis of cell extracts from C2C12 grown in GM or DM in the
presence or absence of SB, probed with antibodies against indicated proteins. GAPDH served as loading control. Inhibition of KMT1A phosphorylation
was observed by SB-treatment-induced blockade of p38a activation in cells under DM conditions. d Western blot analysis of cell extracts from C2C12
cells expressing scramble control shRNA (Ctrl) or p38αshRNA via lentiviral delivery grown as specified in GM or DM, probed with antibodies for indicated
proteins, where GAPDH for loading control. Inhibition of KMT1A phosphorylation was observed by p38α knockdown. e Control IgG or anti-Flag (M2)
immunoprecipitates were retrieved as indicated from extracts of 293A cells expressing with or without Flag-KMT1A via lentiviral delivery. These
immunoprecipitates were then subjected to in vitro kinase assay in the presence of purified p38α with or without SB. Subsequently, the reaction
mixture was divided equally and evaluated one part for autoradiography and another part for western blot analysis. Phosphorylation of KMT1A directly
by p38α was observed
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KMT1A association with MyoD after elevating p38α ac-
tivity by MKK6EE overexpression via lentiviral delivery
in C2C12 cells grown in GM by western blot analysis.
As controls, cells overexpressing MKK6DN or empty
vector control (Em) via the same manner were grown in
both GM and DM, respectively. The analysis shows
MyoD in anti-KMT1A immunoprecipitates from above
Em control cells in GM but not in DM, as anticipated
(Fig. 5c). Remarkably, this recovery of MyoD was not
observed in cells overexpressing MKK6EE in GM al-
though comparable levels of KMT1A were recovered
from extracts all these cells, indicating that MKK6EE-
p38α activation displaces KMT1A from MyoD from cells
even in conditions non-permissible for differentiation.
To test if this presence or absence of MyoD with
KMT1A is mirrored to its activity associated with MyoD,
an in vitro HMTase activity assay was performed in anti-
MyoD immunoprecipitates retrieved from these cells ex-
tracts. Results show the loss of MyoD-associated activity
in GM only in MKK6EE overexpressing cells. Western
blot analysis (Additional file 5: Figure S5A) confirmed
the protein expression of both MKK6EE and MKK6DN,
which are tagged with HA as described above (Fig. 2), in
these cells. Results of an in vitro kinase assay performed
in anti-phospho p38 immunoprecipitates using bacter-
ially purified GST-ATF2 protein as for substrate also
confirm elevated p38α activity in cells overexpressing
MKK6EE but not MKK6DN or vector control cells cul-
tured in GM and activated p38α in vector control cells
in DM as expected (Additional file 5: Figure S5B). Taken
together, these results demonstrate that elevated p38α
activity results in KMT1A phosphorylation and its dis-
sociation from MyoD during myoblast differentiation.
Activation of p38α eradicates KMT1A-directed H3K9me3
marks at the myogenin promoter
Results above demonstrate that p38α-dependent phos-
phorylation of KMT1A results in its removal from
MyoD and myogenic differentiation. We asked whether
this event contributes to alterations in chromatin at the
promoters of myogenic genes relevant to differentiation.
We primarily focused on the promoter of Myog, at
which MyoD-associated KMT1A establishes transcrip-
tionally repressive H3K9me3 marks prior to activation of
differentiation [25, 26]. We sought to determine if p38α
activation-associated MyoG expression, and in turn dif-
ferentiation, is controlled through eradication of KMT1A-
directed H3K9me3 from the promoter of this gene.
Fig. 5 p38α unleashes KMT1A via phosphorylation from MyoD during differentiation. a Control IgG or anti-MyoD immunoprecipitates retrieved
from cell extracts of C2C12 cells grown GM or DM with or without SB were divided equally and evaluated one part for western blot analysis,
probed with antibodies against KMT1A and MyoD. Another part was subjected to HMT activity assay. Methylated and input H3(N) were detected
by fluorography and Commassie, respectively. b Control IgG or anti-KMT1A immunoprecipitates retrieved from cell extracts used in a were subjected
to western blot analysis, probed with antibodies against MyoD and KMT1A. c Control IgG, anti-KMT1A, or anti-MyoD immunoprecipitates were retrieved
from cell extracts of C2C12 cells expressing vector control (Em), MKK6EE or MKK6DN via lentiviral delivery grown in GM or DM. Subsequently, IgG and
KMT1A immunoprecipitates were subjected to western blot analysis, probed with antibodies against MyoD and KMT1A. Separately, IgG and MyoD
immunoprecipitates were subjected to HMT activity assay. Methylated and input H3(N) were detected by fluorography and Commassie, respectively
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Therefore, ChIP assay was performed for H3K9me3
and KMT1A levels on Myog promoter in C2C12 cells
grown in GM or DM treated without or with SB. Re-
sults show that a decrease in H3K9me3 is accompanied
by a loss of KMT1A levels in C2C12 cells upon induc-
tion to differentiate by switching from GM into DM
(Fig. 6a, left panel), as reported previously [26]. Import-
antly, the levels of H3K9me3 and KMT1A at the Myog
promoter are persistent in SB-treated cells grown in
DM, indicating that the loss of H3K9me3 and KMT1A at
this promoter is dependent on p38α activation during the
differentiation. Consistent with previous studies [22, 23],
we failed to observe the repressive H3K27me3 marks at
the Myog promoter in growing C2C12 myoblasts (GM).
Results of ChIP analysis further show that increased
binding of MyoD and p38α at this gene promoter was
not substantially altered by blockage of p38α activation
in C2C12 cells treated with SB in DM, in agreement
with previous studies [30, 31]. In addition to Myog pro-
moter, ChIP assay was performed for these conditions
at the promoter of MyHCIIb, a lately expressed myo-
genic gene targeted for H3K27me3-mediated repression
[23] which utilizes the combined activity of MyoD and
MyoG for its acivation [27]. In contrast to MyoG, re-
sults show no enrichment of KMT1A or H3K9me3.
However, consistent with described study, H3K27me3
was detected on MyHCIIb promoter in myoblasts and
retained in SB-treated cells induced to differentiate in
DM (Fig. 6a, right panel). Further, we found that both
MyoD and p38α were enriched on MyHCIIb promoter on
induction of differentiation and remained unchanged fol-
lowing SB treatment. To confirm the specificity of ChIP
assay, PCR was performed on non-muscle amylase pro-
moter and detected no binding for the above investiga-
tions (data not shown). These results indicate that the
p38α activity eradicates KMT1A, thereby depleting its re-
strictive H3K9me3 mark from the Myog promoter during
myoblast differentiation. We further tested whether ele-
vated p38α activity by MKK6EE is sufficient to remove the
KMT1A-mediated H3K9me3 marks from the Myog pro-
moter in growing myoblasts. Therefore, ChIP assay was
performed for determining the levels of KMT1A and
H3K9me3 on the promoter of Myog after MKK6EE
overexpression via lentiviral delivery in C2C12 cells cul-
tured in GM. Strikingly, both KMT1A and H3K9me3
are lost from the Myog promoter in C2C12 cells ex-
pressing MKK6EE but not vector control (Em), while
treatment with SB partially recovered their loss in
MKK6EE-expressing cells (Fig. 6b). Collectively, these
results demonstrate that p38α activation dampens repres-
sive H3K9me3 marks from Myog in part by removing
KMT1A bound with MyoD at the onset of C2C12 cells
differentiation.
Activation of p38α permits histone H3 lysine 9 acetylation
at the myogenin promoter
Activation of Myog is accompanied with a switching
from repressive methylation to activating acetylation of his-
tone H3 at the promoter of this gene during myoblast dif-
ferentiation [24, 25, 31]. Since methyl/acetyl modifications
Fig. 6 Inhibition of p38α activation retains KMT1A on chromatin of the myogenin promoter during differentiation. a ChIP analysis of E box-containing
regions within the Myog and MyHCIIB promoters was performed on chromatin of C2C12 cells gown in GM or DM treated with or without SB. Schematic
diagram represents E box-containing regions of these genes promoters and arrows indicate primers used for PCR reaction. ChIP was performed with
antibodies against proteins as indicated, where no antibodies or IgG were used as controls. b ChIP analysis of same regions of Myog promoter was
performed on chromatin of C2C12 cells expressing vector control (Em) or MKK6EE vial lentiviral delivery grown in GM in the presence or absence of SB.
ChIP was performed with anti-H3K9me3 or anti-KMT1A antibodies, where no antibodies or IgG were used as controls
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fail to occur concurrently at the same lysine residue, we
tested whether preclusion of KMT1A-mediated H3K9
methylation by p38α activity (Fig. 6) permits acetylation of
H3 at this residue (H3K9ac) on the promoter of Myog to
promote its activation during myoblasts differentiation.
Therefore, ChIP assay was performed for H3K9ac on the
Myog promoter in C2C12 cells grown in GM or DM with
or without SB treatment. Consistent to our previous study
[24], results show an enrichment of H3K9ac on the pro-
moter of Myog in differentiating C2C12 cells grown in DM
(Fig. 7a). However, this enrichment was not observed in
cells exposed with SB. Studies have demonstrated that the
chromatin recruitment of histone acetyltransferases p300/
PCAF increases global H3 acetylation (H3ac) at the Myog
promoter on induction of C2C12 cells differentiation
[24, 31] and that these activities were not affected after
p38α inhibition in cells treated with SB [31]. Our re-
sults also show no alteration of total H3ac on the Myog
promoter in C2C12 cells following SB treatment in
DM, suggesting that the blockade of p38α precluded
specifically H3K9ac at this promoter (Fig. 7a). To con-
firm that p38α activation was blocked, we performed
ChIP assay for Brg1, a critical component of SWI/SNF
chromatin remodeling complex recruited to the Myog
promoter in a p38α activity-dependent manner [31].
Results show as reported previously that Brg1 was re-
cruited to the Myog promoter of C2C12 cells in DM,
while treatment with SB blocked this recruitment
(Fig. 7a). Together, these results demonstrate that p38α
activity is necessary for the acetylation at H3K9 on the
Myog promoter at the onset of myoblasts differenti-
ation. We then tested whether p38α activity is sufficient
for the above event. Hence, ChIP assay was performed
for H3K9ac on the Myog promoter in C2C12 cells cul-
tured in GM after expression of MKK6EE via lentiviral
delivery followed by treatment without or with SB. Results
show the enrichment of H3K9ac at this promoter in cells
expressing MKK6EE compared to vector control (Em)
and that this increase of H3K9ac is inhibited by SB
treatment (Fig. 7b), providing further evidence for p38α
activity in orchestrating acetylation of H3K9 on the
Myog promoter. Collectively, these results establish a
critical role for p38α activity in authorizing transcrip-
tionally active H3K9 acetylation at the Myog promoter
on the induction of C2C12 myoblast differentiation.
Discussion
In this study, we set out to understand how MyoD can
dissociate from KMT1A in proliferating myoblasts to ac-
tivate MyoD-target genes upon induction to differentiate
into myotubes. Here, we conclusively demonstrate an in-
tegral role for p38α activity in releasing KMT1A from
MyoD to activate muscle gene expression on the onset
of differentiation. Specifically, we show p38α activity-
dependent phosphorylation of KMT1A during differenti-
ation and that phosphorylated KMT1A releases from
chromatin-bound MyoD within the promoter of tran-
scriptionally repressed Myog in proliferating myoblasts.
This dismissal of KMT1A results in a decline of tran-
scriptionally repressive H3K9me3 mark at the Myog pro-
moter and an enrichment of permissive acetylated H3K9
and the expression of MyoG, which plays a critical and
unique role in MyoD regulated differentiation program.
Thus, our findings establish that p38α-directed uncoup-
ling of MyoD/KMT1A complex ensures the eradication
of the repressive H3K9me3 mark, facilitating the forma-
tion of a transcriptionally active chromatin state at myo-
genic loci on the onset of muscle differentiation.
MyoD serves as a central controller of the myogenic
gene expression network for skeletal muscle differentiation
Fig. 7 Blockade of p38α precludes acetylation at histone H3 lysine 9 on the chromatin of myogenin promoter during differentiation. a ChIP analysis of
E box-containing promoter region of Myog was performed on chromatin used in Fig. 6a with indicated anti-acetylated histone H3 and Brg1 antibodies.
In parallel, Input and IgG or no antibodies as controls were processed. b Similar to a, except ChIP performed with anti-acetylated H3 lysine 9 antibodies
on chromatin used in Fig. 6b
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to proceed [4, 7]. MyoD binds and regulates myogenic
genes through repression of these targets in proliferating
myoblasts but can be activated only upon receiving sig-
nals that launch differentiation [4, 5, 19, 52]. In fact,
signals regulating MyoD interactions with cofactors, in-
cluding chromatin modifiers, are critical for fine-tuning
chromatin status of myogenic genes and determining
the net outcome [30–33]. We previously demonstrated
that assembly of KMT1A through interaction with
MyoD at the Myog promoter represses its premature
expression in proliferating myoblasts [26]. In this con-
text, a study has shown that p38γ supports the inter-
action of KMT1A with MyoD via phosphorylation [33].
However, it is well known that p38α acts oppositely to
p38γ to promote MyoD-mediated myogenic gene ex-
pression and differentiation [53, 54], a situation where
KMT1A unleashes from MyoD [26]. Interestingly, here
we found that KMT1A remains associated with MyoD
after inhibition of p38α in myoblasts induced to differenti-
ate, indicating that p38α may directly target KMT1A for
disengaging with MyoD, thereby influencing myogenic
gene expression. Although p38α activates myogenic gene
expression by directly targeting positive chromatin modi-
fier/transcriptional regulator of MyoD [2, 28, 30, 46, 53],
we previously demonstrated that KMT1A overexpression
entirely abolishes ability of myoblasts to differentiate [26].
Interestingly, results show that KMT1A overexpression
moderately affected p38 activation in myoblasts, likely due
to failure of these cells to amplify the differentiation signal.
In this cell background, we hypothesized that this level of
p38α activity may be inadequate to overcome inhibition of
myogenic differentiation by KMT1A overexpression,
since p38 activity status is critical in deciding the extent
of myogenic differentiation [2, 44]. Indeed, we found
that MKK6EE-p38 activation, where MKK6EE overex-
pression results in the activation of primarily p38α [33],
is quite proficient in rescuing KMT1A-inhibited MyoD
function to induce myogenic gene expression and
phenotypic differentiation under both growth and dif-
ferentiation conditions. Note that KMT1A overexpres-
sion does not prevent activation of p38α by MKK6EE,
indicating that KMT1A indeed acts downstream of p38α
activity. Further, this effect of MKK6EE-p38α was blocked
in cells treated with SB and induced to differentiate.
Together, these findings suggest that p38α actively par-
ticipates in disengaging KMT1A-mediated suppression
of MyoD-regulated myogenic differentiation.
KMT1A is a phosphoprotein and that phosphorylation
modulates its function [55–57]. We found that KMT1A
phosphorylation increases in myoblasts on induction of
differentiation, a finding consistent to our previous study
[26]. Further, we found a strong correlation between
differentiation-induced levels of p38 activation and phos-
phorylated KMT1A status, and that MKK6EE-p38α
activation results in increased phosphorylation of KMT1A
in myoblasts. This p38α-coupled KMT1A phosphoryl-
ation is also clearly reflected in MyoD-regulated gene ex-
pression during differentiation. These findings suggest
that p38α activity likely mediates the phosphorylation of
KMT1A in promoting MyoD function on inducing myo-
blast differentiation. Studies have indicated that CDK-
dependent phosphorylation of KMT1A controls its func-
tion during cell cycle progression [55, 57]. Our data show
that inhibition of p38α via SB treatment or shRNA-
mediated knockdown blocks KMT1A phosphorylation
during myoblast differentiation, strongly emphasizing that
p38α activity directed KMT1A phosphorylation in this
process. Indeed, in vitro kinase assay confirms that
KMT1A is a direct target of p38α. Once activated, p38
phosphorylates serine/threonine residues of the substrates.
A previous report has indicated that KMT1A is preferably
phosphorylated at serine residues and that seven putative
phosphorylation sites exist within it. Of these, four are in
the C-terminal, one at the beginning of SET and two
around the chromo domains [55]. Currently, we are in the
process to identify p38α target site(s) on the KMT1A and
their impact to myogenic differentiation.
Previously, we demonstrated that KMT1A association
with MyoD restrains its function in contributing to prolif-
eration by preventing myogenic differentiation [26]. p38γ-
directed phosphorylation of MyoD has been shown to
assist this association with KMT1A, thereby influencing
this myogenic decision [33]. By contrast, it is well recog-
nized that p38α directly targets positive epigenetic and
transcriptional regulators via phosphorylation to allow
their assembly and/or association with MyoD to promote
myogenic differentiation. For instance, phosphorylation of
chromatin-associated factor BAF60c in a MyoD-BAF60c
complex facilitates the recruitment of SWI/SNF chroma-
tin remodeling complex to myogenic loci for gene activa-
tion [28, 46]. Likewise, p38α phosphorylates MEF2, a
transcription factor cooperating with MyoD for both its
recruitment and expression of late myogenic genes in a
feed-forward mechanism [2, 13, 58], and enforces its re-
cruitment of Ash2L/MLL2 methyltransferase complexes
to activate myogenic loci [4, 30]. Additionally, p38α-
mediated phosphorylation of Ezh2 methyltransferase, a
negative epigenetic regulator of myogenic differentiation
[23], has been shown to enhance its interaction with YY1
in repressing Pax7 expression, critical for switching
myoblasts from proliferation into differentiation [59].
Interestingly, we found p38α-directed phosphorylation
of KMT1A during the transition from proliferation into
differentiation of myoblasts. Because the presence of a
KMT1A/MyoD complex is restricted to proliferating myo-
blasts [26], p38α may engage in phosphorylation-mediated
removal of KMT1A from MyoD during differentiation.
Indeed, data of immunoprecipitation-coupled western or
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HMTase activity assays show that KMT1A remains associ-
ated with MyoD only after blockade of p38α activation on
the induction of differentiation, similar to proliferating
myoblasts. Conversely, this association of KMT1A with
MyoD was abolished in proliferating myoblasts after
MKK6EE-p38α activation. Thus, our findings emphasize
that p38α releases KMT1A from MyoD via phosphoryl-
ation at the onset of myoblasts differentiation, thereby res-
cuing MyoD from this negative epigenetic regulator of
myogenic gene expression. KMT1A has been shown to
participate in forming a multimeric complex including
histone methyltransferase G9a [60]. In proliferating
myoblasts, G9a interacts with MyoD and inhibits its
transcriptional activity via methylation to impede myo-
genic differentiation [61]. It is possible that p38α-directed
dissociation of KMT1A might also assist the removal of
G9a from MyoD for influencing myogenic gene expres-
sion during proliferation to differentiation switch of
myoblasts.
Studies have shown that MyoD binds to chromatin of
myogenic genes both in proliferating and differentiated
myoblasts [5, 19]. However, the decision to repress or
activate myogenic gene expression in differentiation de-
pends on the engagement of specific signaling mediators
and chromatin modifiers at the myogenic loci [4, 14, 62].
In this context, assembly of KMT1A/MyoD complex by
p38γ establishes H3K9me3-dependent transcriptionally
repressive chromatin state of Myog during myoblast
proliferation [26, 33]. It is worth noting that Myog is an
important myogenic regulator of differentiation, and
that its suppression during proliferation is critical to
allow for the appropriate expansion of precursor myo-
blasts. In contrast to p38γ, however, p38α coordinates
the assembly of cofactors responsible for achieving per-
missive chromatin architecture during the switch from
proliferation-to-differentiation in myoblasts [28, 30, 31]. A
recent study has indicated that p38α exerts this myogenic
function, in part, via binding and acting at chromatin [54].
Nonetheless, we demonstrated that the eradication of
KMT1A-mediated repressive H3K9me3 methylation is
coupled with permissive H3K9ac marked chromatin of
Myog during myoblasts transition from proliferation-to-
differentiation [26]. Of interest, we observed that the
blockade of p38α activity during this transition, however,
sustains KMT1A engagement along with H3K9me3, and
opposes H3K9ac at the chromatin of Myog promoter. Al-
ternatively, MKK6EE-p38α activation shows removal of
both KMT1A and H3K9me3 coupled with an enrichment
of H3K9ac on the Myog promoter in proliferating myo-
blasts. Thus, these findings clearly demonstrate that p38α
activity is critical for disengaging the KMT1A-imposed
repressive H3K9me3 to facilitate H3K9ac-permissive
chromatin state of Myog at the onset of myoblasts
differentiation.
Conclusions
Collectively, results in this study uncover p38α-KMT1A
signaling as an integral myogenic transcriptional regulatory
system in which phosphorylation uncouples KMT1A from
MyoD to allow a switch from repressive to permissive chro-
matin, allowing the initiation of myogenic gene expression
during myoblasts differentiation. Given that higher levels of
KMT1A contribute to impaired myogenic differentiation in
alveolar subtype of rhabdomyosarcoma [38], and that p38
activity is deficient in a majority of rhabdomyosarcoma
tumors regardless their subtype [39], it remains to be
determined whether and to what extent dysregulated
p38γ/α-KMT1A signaling axis contributes to restraining
rhabdomyosarcoma differentiation, a question of thera-
peutic significance.
Additional files
Additional file 1: Figure S1. Knockdown of p38α was monitored by
western blot analysis of cell extracts from primary HsMB cells expressing
control scramble shRNA (Ctrl) or p38α shRNA, probed with antibodies for
p38α, total p38, β-actin as loading control. Decreased levels of both p38α
and total p38 were observed by p38α shRNA relative to Ctrl shRNA.
(PPTX 47 kb)
Additional file 2: Figure S2. (A) Ectopic Flag-KMT1A expression was
determined by western blot analysis of C2-4RE-luc and C2-4RE-Luc/
KMT1A-F cells grown in GM, probed with antibodies to Flag-KMT1A, total
KMT1A, MyoD, and β-actin as loading control. Flag-KMT1A expression
was observed only in C2-4RE-luc/KMT1A-F cells. (B) Luciferase activity was
monitored in C2-4RE-luc cells expressing vector control (Em), MKK6EE or
MMK6DN grown in GM and values expressed after protein normalization
as fold activation. Error bar, ±SEM (n= 3). MyoD-responsive reporter luciferase
gene activation was observed by MKK6EE but not MKKDN in these cells.
(PPTX 59 kb)
Additional file 3: Figure S3. The levels of phosphor-p38 as an indicator
of its activated status was monitored by western blot analysis of indicated
cells grown in GM or DM in the presence or absence of SB, probed with
anti-phospho-p38 and anti-p38 antibodies, where the later antibodies
used for monitoring the equivalent levels of total p38 in cell extracts.
(PPTX 57 kb)
Additional file 4: Figure S4. Western blot analysis verified phosphorylated
KMT1A by re-probing the membrane of the western blot results presented in
Fig. 4a with a separate KMT1A antibody. (B) Western blot analysis of C2C12
cells expressing control scramble shRNA (Ctrl) or KMT1A shRNA via lentiviral
delivery grown in GM or DM, probed with antibodies against KMT1A,
and β-actin as loading control. Decreased levels of both under- and
phosphorylated KMT1A were observed by KMT1A shRNA relative to Ctrl.
(C) Flag-KMT1A overexpression was monitored by western blot analysis
of cell extracts following it expression in 293A cells (293A-KMT1A-F) via
lentiviral delivery. (D) In vitro kinase assays was performed for p38α activity
using GST or GST-ATF2 as substrate by in vitro kinase assays in the presence
and absence of SB. Commassie and autoradiography detected inputs
GST/GST-ATF2 proteins and phosphorylated ATF2, respectively.
(PPTX 99 kb)
Additional file 5: Figure S5. Expression of HA-tagged MKK6EE and
MKK6DN in C2C12 cells was verified by western blot analysis, probed with
antibodies against HA, and β-actin as loading control. (B) Control IgG or
anti-phospho-p38 immunoprecipitates retrieved from extracts of indicated
cells grown in GM or DM were subjected to in vitro kinase assays to monitor
p38 activation using GST-ATF2 as substrate. Autoradiography and Commassie
detected phosphorylated ATF2 and GST-ATF2 protein, respectively.
(PPTX 75 kb)
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